Xsolla Partners With Day of the Devs for 2025 to Support New Game Development and Launches at Key Events
13.2.2025 10:00:00 CET | Business Wire | Press release
Day Of The Devs Powered By Xsolla Will Celebrate Creativity And Bring Opportunities Together For Game Developers Of All Genres, Backgrounds, And Locations
Xsolla, a leading global video game commerce company, announces its 2025 flagship sponsorship for Day of the Devs, a non-profit organization celebrating video games' creativity, diversity, and magic. This announcement underscores Xsolla's commitment to empowering game developers and bringing together opportunities for creative talent and development worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213515388/en/
(Graphic: Xsolla)
“This partnership and collaboration underscores our ongoing mission to empower developers and make great games more accessible worldwide no matter what size or where they are from,” said Berkley Egenes, Chief Marketing & Growth Officer. “Day of the Devs powered by Xsolla provides an unparalleled platform to support diverse talent and creativity and create a channel to bring opportunities together for developers, and we are proud to be a part of this initiative.”
Day of the Devs, powered by Xsolla, will include incredible events and opportunities for video game developers to showcase their new games and connect with industry leaders to help them build their gaming businesses. Kicking off 2025, Day of the Devs: San Francisco Edition will take place on Sunday, March 16, 2025, at The Midway in San Francisco, bringing thousands of indie fans and developers together to play incredible hand-picked titles. More details on the event can be found on the Eventbrite page here.
Continuing the celebration, Day of the Devs: GDC Edition will feature a selection of titles from the San Francisco Edition at the Moscone Center during the Game Developers Conference (GDC) 2025, running from March 17 to 21 on the 3rd floor of Moscone West. Attendees can explore these unreleased games during regular hours, while the public, 18 and older, can experience them during GDC Nights on Monday and Thursday evenings from 6:30 PM to 10:00 PM PT. Xsolla will also be hosting a lounge on the first floor of Moscone West to support the community and provide an area for developers to collaborate with the Xsolla team.
Day of the Devs, a non-profit organization, has celebrated video games' creativity, diversity, and magic for over 13 years. It has hosted thousands of attendees at physical events, reached millions through virtual showcases, and provided a platform for hundreds of games and developers.
“This event embodies the spirit of creativity and community that defines indie games,” said Greg Rice, Head Curator at Day of the Devs. “Thanks to partners like Xsolla, we can continue to keep these events free and accessible, allowing thousands to connect with the magic of games and the talent behind them.”
Through this sponsorship, Xsolla will engage with hundreds of game developers to support their initiatives and bring opportunities together to solve inherent questions and challenges facing their funding, distribution, and monetization efforts. This flagship sponsorship reinforces Xsolla’s commitment to supporting game developers to provide the same opportunities and connections to any game - regardless of size, location, genre, or platform. For more information, please visit: xsolla.blog/dotdgdc
About Xsolla
Xsolla is a leading global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.
For more information, visit xsolla.com
About Day of the Devs
Day of the Devs is a non-profit with the mission to celebrate the creativity, diversity and magic of video games. Day of the Devs gives a voice to emerging or underrepresented talent with platforms that connect players with developers, and their games. Day of the Devs takes on the form of virtual and physical events – all completely free, with no costs to either developers or attendees. Over the last 13 years, Day of the Devs has shined a spotlight on many hundreds of games, hosted tens of thousands of people at in-person events, and reached out to millions of viewers through virtual showcases.
For more information, visit dayofthedevs.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213515388/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom